Use of Contrast-Enhanced Mammography in Breast Cancer Screening

Maxine S. Jochelson
DOI: https://doi.org/10.1007/978-3-030-11063-5_7
2019-01-01
Abstract:Multiple randomized control trials have demonstrated that screening mammography reduces breast cancer mortality by approximately 30%. Mammography is relatively inexpensive and widely available. Unfortunately, its sensitivity is limited—particularly in high-risk women with dense breasts—falling from 70–85% to approximately 50%. Additionally, false-positive findings lead to anxiety, producing call backs and biopsies with benign results. Recently, digital breast tomosynthesis has been shown to slightly improve sensitivity and significantly reduce the number of call backs and false-positive biopsies. Supplemental imaging with screening ultrasound is also widely used to help detect cancers, finding approximately 3.5 additional cancers per 1000 women. The most sensitive examination, however, is contrast-enhanced breast MRI. This superior sensitivity is primarily related to its ability to image enhancement of neovascularity. In women at greater than 20% risk for developing cancer, yearly MRI in addition to mammography is the accepted standard of care. However, MRI is expensive and not consistently available enough to perform routine screening in a larger population of women including those at intermediate risk or those with dense breasts. Contrast-enhanced digital mammography has been developed to image enhancing neovascularity in a fashion like MRI, using iodinated contrast with an adapted digital mammography platform.
What problem does this paper attempt to address?